Results 161 to 170 of about 92,598 (348)

Endoscopic Submucosal Dissection for Early Esophageal Squamous Cell Carcinoma Located at Esophageal Varices Caused by Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Wenlan Zheng, Jinzhong Yu, Kun Liu, Xiaona Lu, Xuemei Zhang, Jia Shi, Shihan Yu, Wurong Du, Hai Feng, Fu Li, Biao Gong, Yueqiu Gao, Zhuo Yu   +12 more
wiley   +1 more source

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure

Alimentary Pharmacology &Therapeutics, EarlyView.
Between 2012 and 2021 in France, invasive fungal diseases affected 1 in 50 patients with alcohol‐related hepatitis and at least two hepatic or extrahepatic complications, with substantially higher mortality than bacterial pneumonia. These findings support targeted screening and early antifungal strategies in this population, as currently recommended ...
Charlotte Mouliade, Lucia Parlati, Stylianos Tzedakis, Mathis Collier, Samir Bouam, Philippe Sogni, Fanny Lanternier, Alexandre Alanio, Vincent Mallet, Demosthenes Research Group   +9 more
wiley   +1 more source

Interventional embolisation for patients with cirrhosis and recurrent or persistent hepatic encephalopathy related to spontaneous portosystemic shunts: protocol for a prospective, non-randomised controlled study [PDF]

Qiao Ke, Ting Lin, Xiao-Juan Lei, Xiadi Weng, Jian He, Xinhui Huang, Ling Li, Wuhua Guo   +7 more
openalex   +1 more source

The Prevalence, Predictors, and In-Hospital Mortality of Hepatic Encephalopathy in Patients with Liver Cirrhosis Admitted at St. Dominic Hospital in Akwatia, Ghana [PDF]

, 2020
Amoako Duah, Adwoa Agyei‐Nkansah, Foster Osei‐Poku, Francisca Duah, Daniel Ampofo-Boobi, Bright Peprah   +5 more
openalex   +1 more source

Successful Embolization for Recurrent Encephalopathy Caused by Type II Abernethy Malformation

Portal Hypertension &Cirrhosis, EarlyView.
Hongliang Wang, Shoujin Cao, Chunhui Nie, Baoquan Wang, Bin Xiong   +4 more
wiley   +1 more source

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

Alimentary Pharmacology &Therapeutics, EarlyView.
We evaluated long‐term outcomes following nucleos(t)ide analogue discontinuation in HBeAg‐negative chronic hepatitis B. HBsAg loss was infrequent. Early HBsAg loss occurred in patients with low end‐of‐treatment HBsAg levels and without ALT flare, whilst late HBsAg loss typically followed ALT flares and was associated with higher end‐of‐treatment HBsAg ...
Simon J. Hume, Samuel Hall, Gareth Burns, Sara Vogrin, Daniel Tassone, Paul Desmond, Dilip Ratnam, Miriam T. Levy, Rohit Sawhney, Amanda Nicoll, Zina Valaydon, Simone I. Strasser, Meng Ngu, Marie Sinclair, Chris Meredith, Gayle V. Matthews, Kumar Visvanathan, Jacinta A. Holmes, Alexander J. Thompson   +18 more
wiley   +1 more source

ASSESSMENT OF THE DYNAMICS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS BEFORE AND AFTER IN-HOSPITAL TREATMENT

, 2022
Bekmuradova Makhsuda Salkhidinovna
openalex   +1 more source

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Features of clinically significant portal hypertension (CSPH) in patients with autoimmune hepatitis indicate a substantial risk for decompensation and impaired transplant‐free survival. Non‐invasive risk prediction based on liver stiffness measurement ≥ 15 kPa and/or thrombocytopenia (< 150 G/L) serves as a valuable surrogate to identify patients at ...
Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S. Hofer, Mattias Mandorfer, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger, Albert F. Stättermayer   +10 more
wiley   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Hepatic Encephalopathy

Gastroenterology, 1979
A M, Hoyumpa, P V, Desmond, G R, Avant, R K, Roberts, S, Schenker   +4 more
openaire   +2 more sources